GHK-Cu + KPV: Stack Composition, Research & Concentration Guide
GHK-Cu + KPV is a two-component research-market peptide blend containing copper tripeptide GHK-Cu and the C-terminal α-MSH fragment KPV. It is a mixture of two separately characterized compounds, not a single peptide or universally standardized clinical formulation. Marketed formulations documented in current sources include 50 mg GHK-Cu + 10 mg KPV and 50 mg GHK-Cu + 20 mg KPV.
Importantly, evidence for either peptide individually does not establish that the combination is effective or safe. No published controlled human study evaluating the exact GHK-Cu + KPV combination was identified in the reviewed literature.
GHK-Cu + KPV Stack Snapshot
GHK-Cu + KPV Composition Diagram
This visual represents the stack as two independent peptide components. The vial contains the stated mass of each component; the masses should never be added together and then treated as the concentration of each individual peptide.
What Is GHK-Cu + KPV?
GHK-Cu + KPV is best described as a two-peptide research mixture. GHK-Cu is a copper-associated form of the tripeptide Gly-His-Lys, while KPV is the C-terminal tripeptide Lys-Pro-Val derived from α-melanocyte stimulating hormone (α-MSH).
The name GHK-Cu + KPV is descriptive rather than a recognized pharmaceutical or pharmacopoeial name. It identifies the two components but does not, by itself, establish a fixed ratio, manufacturing specification, clinical indication, stability profile, or validated combination effect.
What's in GHK-Cu + KPV?
GHK-Cu
GHK-Cu is a copper-associated tripeptide studied extensively in fibroblast, extracellular-matrix, wound and tissue-remodeling research.
Component-level evidenceKPV
KPV is the C-terminal tripeptide fragment of α-MSH. Research has examined its anti-inflammatory signaling in cellular systems and animal models, including experimental intestinal inflammation.
Primarily preclinical evidenceEvidence for Each Component
GHK-Cu
Preclinical + human topical researchEarly laboratory work found that GHK-Cu can stimulate collagen synthesis in cultured fibroblasts. Animal studies have also examined extracellular-matrix accumulation and wound-healing endpoints.
Human evidence exists mainly in topical/cosmetic contexts and remains considerably smaller and less definitive than the preclinical literature.
KPV
Cellular + animal researchKPV has been investigated as an anti-inflammatory peptide in cellular models and mouse models of intestinal inflammation. Research has examined pathways including NF-κB-related inflammatory signaling and peptide transport.
These findings should not be interpreted as evidence of established clinical efficacy in humans.
GHK-Cu + KPV
Combination evidence gapThe literature identified for this page does not establish a controlled human trial of the exact GHK-Cu + KPV blend.
Therefore, component-level mechanisms cannot be converted into a claim that the combined formulation is synergistic, effective, or clinically validated.
Has the Complete GHK-Cu + KPV Combination Been Clinically Studied?
Published evidence for GHK-Cu and KPV should therefore remain separated into two evidence streams. A GHK-Cu experiment is not a GHK-Cu + KPV experiment, and a KPV experiment is not a GHK-Cu + KPV experiment.
| Evidence category | GHK-Cu | KPV | GHK-Cu + KPV |
|---|---|---|---|
| Cell / in-vitro research | Yes | Yes | No identified combination study |
| Animal research | Yes | Yes | No identified exact-blend study |
| Human clinical research | Limited, mainly topical/cosmetic contexts | No established clinical efficacy evidence identified | No identified controlled human study |
| Validated combination protocol | Not applicable | Not applicable | No |
Common GHK-Cu + KPV Formulations
Current research-market documentation shows more than one composition. The most important distinction is between 50 mg GHK-Cu + 10 mg KPV and 50 mg GHK-Cu + 20 mg KPV. These are not mathematically interchangeable because the KPV concentration changes when the same liquid volume is used.
| Formulation | GHK-Cu | KPV | Total stated peptide mass | Standardized? |
|---|---|---|---|---|
| Configuration A | 50 mg | 10 mg | 60 mg | No established universal standard |
| Configuration B | 50 mg | 20 mg | 70 mg | No established universal standard |
GHK-Cu + KPV Concentration Logic
Adding more liquid does not change the mass of peptide in the vial. It changes the concentration because the same component mass is distributed through a larger final volume.
GHK-Cu + KPV Reconstitution & Concentration
For mathematical concentration purposes, use the stated mass of each component and the final liquid volume. Do not combine the masses and report one concentration for both peptides.
Component concentration (mg/mL)
= component mass (mg) ÷ final liquid volume (mL)
Example: 50 mg GHK-Cu + 10 mg KPV
| Final liquid volume | GHK-Cu | KPV | Total peptide mass |
|---|---|---|---|
| 1 mL | 50 mg/mL | 10 mg/mL | 60 mg total |
| 2 mL | 25 mg/mL | 5 mg/mL | 60 mg total |
| 3 mL | 16.67 mg/mL | 3.33 mg/mL | 60 mg total |
| 5 mL | 10 mg/mL | 2 mg/mL | 60 mg total |
Alternative example: 50 mg GHK-Cu + 20 mg KPV
| Final liquid volume | GHK-Cu | KPV | Total peptide mass |
|---|---|---|---|
| 1 mL | 50 mg/mL | 20 mg/mL | 70 mg total |
| 2 mL | 25 mg/mL | 10 mg/mL | 70 mg total |
| 3 mL | 16.67 mg/mL | 6.67 mg/mL | 70 mg total |
| 5 mL | 10 mg/mL | 4 mg/mL | 70 mg total |
GHK-Cu calculation
Example mass: 50 mg
Example final volume: 5 mL
KPV calculation
Example mass: 10 mg
Example final volume: 5 mL
Why Multi-Component Concentration Is Different
50 mg GHK-Cu + 10 mg KPV = 60 mg total, therefore “60 mg/mL GHK-Cu + KPV.”
That number is only the total peptide mass per mL. It does not tell you the concentration of either individual component.
The correct approach is to preserve the identity of every component:
GHK-Cu = 50 mg ÷ final volume
KPV = 10 mg ÷ final volume
This distinction becomes especially important when comparing different formulations. A 50/10 mg vial and a 50/20 mg vial can have the same GHK-Cu concentration at a given volume while having different KPV concentrations.
Quick Concentration Reference
| Formulation | 1 mL | 2 mL | 3 mL | 5 mL |
|---|---|---|---|---|
| GHK-Cu 50 mg | 50 mg/mL | 25 mg/mL | 16.67 mg/mL | 10 mg/mL |
| KPV 10 mg | 10 mg/mL | 5 mg/mL | 3.33 mg/mL | 2 mg/mL |
| KPV 20 mg | 20 mg/mL | 10 mg/mL | 6.67 mg/mL | 4 mg/mL |
Need to Calculate Another Vial or BAC-Water Volume?
The BacScience Universal BAC Water Calculator is primarily designed around single-compound mathematical calculations. For a multi-component vial such as GHK-Cu + KPV, calculate each component separately using its own stated mass.
Open the BacScience Universal BAC Water Calculator →Why Are GHK-Cu and KPV Combined in Research or Market Practice?
The conceptual rationale for combining the two compounds comes from the fact that they have been investigated in different but potentially overlapping biological areas. GHK-Cu has a literature base involving extracellular-matrix remodeling, collagen-related processes and tissue research, while KPV has been investigated for inflammatory signaling.
However, a mechanistic rationale is not equivalent to experimental validation. Without a study testing both compounds together under a defined formulation, the existence of plausible complementary mechanisms does not establish synergy.
Research Status at a Glance
Research Limitations
- Marketed blend names do not necessarily establish a standardized composition.
- Vendor-declared mass ratios are not equivalent to independent analytical verification.
- Component-level studies cannot be treated as combination studies.
- Preclinical findings cannot automatically be translated into human clinical efficacy.
- The mathematical concentration tables on this page are calculations, not dosing recommendations.
- Actual material identity, purity, water content, salt/complex form and analytical recovery can affect laboratory measurements.
- A COA should identify the individual components separately where possible rather than reporting only one aggregate purity figure.
Regulatory & Safety Considerations
GHK-Cu + KPV should not be presented as an FDA-approved therapeutic combination or as an established clinical treatment protocol.
Research literature concerning GHK-Cu or KPV individually does not establish the safety, compatibility, pharmacokinetics, stability or efficacy of their combined formulation.
Research materials should be evaluated according to applicable institutional laboratory procedures, supplier documentation and local regulations.
Frequently Asked Questions
What is GHK-Cu + KPV?
It is a two-component research peptide mixture containing GHK-Cu and KPV. It is not one molecule and does not have one universally standardized formulation.
Is GHK-Cu + KPV a standardized peptide stack?
No universal standardized formulation was identified. Current research-market listings include different GHK-Cu:KPV ratios, including 50/10 mg and 50/20 mg configurations.
What are the ingredients in GHK-Cu + KPV?
The two components are GHK-Cu, the copper-associated GHK tripeptide, and KPV, the Lys-Pro-Val C-terminal fragment of α-MSH.
Has GHK-Cu + KPV been clinically studied together?
No controlled human study of the exact combination was identified in the reviewed sources. Evidence for the two individual components should therefore remain separate from combination claims.
How does adding BAC water change GHK-Cu concentration?
Mathematically, concentration equals the GHK-Cu mass divided by the final liquid volume. For example, 50 mg divided by 5 mL equals 10 mg/mL.
How does adding BAC water change KPV concentration?
KPV is calculated independently. In a 10 mg KPV formulation, 10 mg divided by 5 mL equals 2 mg/mL.
Can I add the GHK-Cu and KPV masses together?
You can calculate total peptide mass, but you should not use total peptide mass as the individual concentration of GHK-Cu or KPV. Every component requires its own calculation.
Is 50 mg GHK-Cu + 10 mg KPV the only formulation?
No. Current market documentation also identifies 50 mg GHK-Cu + 20 mg KPV. Other formulations may exist, so the vial label or analytical documentation should always be checked.
Does GHK-Cu evidence prove that GHK-Cu + KPV works?
No. Individual-component evidence cannot establish efficacy or safety of the combination.
Does KPV's anti-inflammatory research prove clinical efficacy?
No. Much of the KPV literature is cellular or animal research. Preclinical findings should not be presented as established human therapeutic efficacy.
Scientific References
- Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex GHK-Cu. PubMed
- Maquart FX, et al. In vivo stimulation of connective tissue accumulation by GHK-Cu in experimental wounds. PubMed
- Simeon A, et al. GHK-Cu effects on matrix metalloproteinase-2 and extracellular-matrix remodeling. PubMed
- Parker NP, et al. Effects of topical copper tripeptide complex on wound healing in an irradiated rat model. PubMed
- Getting SJ, et al. Dissection of the anti-inflammatory effect of KPV and related α-MSH peptides. PubMed
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV and inflammatory bowel disease models. PubMed
- Kontermann RE / related research literature on KPV transport and inflammatory signaling. PubMed
Evidence classification: Component-level evidence separated from combination-level evidence. Market formulation observations are not treated as clinical validation.
Need to Calculate Another Vial or BAC-Water Volume?
Use the BacScience Universal BAC Water Calculator for mathematical concentration calculations. For multi-component blends, calculate each component independently.
Open BAC Water Calculator